Back to Search Start Over

Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry.

Authors :
Marí-Alfonso, Begoña
Simeón-Aznar, Carmen Pilar
Guillén-Del Castillo, Alfredo
Rubio-Rivas, Manuel
Trapiella-Martínez, Luis
Todolí-Parra, José Antonio
Rodríguez Carballeira, Mónica
Marín-Ballvé, Adela
Iniesta-Arandia, Nerea
Colunga-Argüelles, Dolores
Castillo-Palma, María Jesús
Sáez-Comet, Luis
Egurbide-Arberas, María Victoria
Ortego-Centeno, Norberto
Freire, Mayka
Vargas Hitos, José Antonio
Chamorro, Antonio-J
Madroñero-Vuelta, Ana Belen
Perales-Fraile, Isabel
Pla-Salas, Xavier
Source :
Seminars in Arthritis & Rheumatism; Jun2018, Vol. 47 Issue 6, p849-857, 9p
Publication Year :
2018

Abstract

Objective To assess the prevalence and causes of hepatobiliary involvement (HBI) in systemic sclerosis (SSc), to investigate the clinical characteristics and prognosis of SSc patients with HBI (SSc-HBI) and without HBI (SSc-non-HBI), and to compare both groups according to the cutaneous SSc subsets. Methods In all, 1572 SSc patients were collected in the RESCLE registry up to January 2015, and all hepatobiliary disturbances were recorded. We investigated the HBI-related characteristics and survival from the entire SSc cohort and according to the following cutaneous subsets: diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), and SSc sine scleroderma (ssSSc). Results Out of 1572, 118 (7.5%) patients had HBI. Primary biliary cholangitis (PBC) was largely the main cause ( n = 67, 4.3%), followed by autoimmune hepatitis ( n = 19, 1.2%), and anti-mitochondrial negative PBC ( n = 6, 0.4%). Other causes of HBI were as follows: secondary liver diseases ( n = 11, 0.7%), SSc-related HBI ( n = 7, 0.4%), nodular regenerative hyperplasia ( n = 3, 0.2%), liver cirrhosis ( n = 3, 0.2%), and HBI of unknown origin ( n = 2, 0.1%). In multivariate analysis, HBI was independently associated to lesser risk of dcSSc (5.1% vs. 24.4%), and higher frequency of calcinosis (26% vs. 18%), left ventricular diastolic dysfunction (46% vs. 27%), sicca syndrome (51% vs. 29%), and anti-centromere antibodies (ACA, 73% vs. 44%). According to the cutaneous subsets, HBI was associated (1) in lcSSc, to longer time from SSc onset to diagnosis (10.8 ± 12.5 vs. 7.2 ± 9.3 years), sicca syndrome (54% vs. 33%), and ACA (80% vs. 56%); (2) in ssSSc, to sicca syndrome (44% vs. 19%), and (3) in dcSSc, no associations were found. HBI was the cause of death in 2.3% patients but the cumulative survival according to the presence or absence of HBI showed no differences. Conclusions HBI prevalence in SSc is 7.5% and dcSSc is the least involved subset. PBC is the main cause of HBI. Patients with SSc-HBI exhibited specific clinical and immunologic profile. Survival is similar for SSc patients with HBI. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00490172
Volume :
47
Issue :
6
Database :
Supplemental Index
Journal :
Seminars in Arthritis & Rheumatism
Publication Type :
Academic Journal
Accession number :
129790814
Full Text :
https://doi.org/10.1016/j.semarthrit.2017.10.004